Daptomycin CAS 103060-53-3 Ubunyulu ≥95.0% API Factory High Purity

Inkcazelo emfutshane:

Igama leKhemikhali: Daptomycin

CAS: 103060-53-3

Imbonakalo: Umgubo oMthubi okanye oMthubi oMthubi

Ubunyulu: ≥95.0% (Ibalwe kwisiseko esomileyo)

I-Daptomycin kunyango lwesikhumba esithile esinzima kunye nosulelo lwezicubu ezithambileyo ezibangelwa yintsholongwane yegram-positive.

Umgangatho ophezulu we-API, iMveliso yoRhwebo

Inquiry: alvin@ruifuchem.com

Thumela i-imeyile kuthi

Iinkcukacha zeMveliso

Iimveliso ezinxulumeneyo

Iithegi zeMveliso

Inkcazo:

Umenzi onobunyulu obuPhezulu kunye noMgangatho oZinzile
Igama leKhemikhali: Daptomycin
CAS: 103060-53-3
Umgangatho ophezulu we-API, iMveliso yoRhwebo

Iipropati zeMichiza:

Igama leMchiza	Daptomycin
Izithethantonye	LY146032
Inombolo yeCAS	103060-53-3
Inombolo yeCAT	RF-API10
Ubume beStokhwe	Kwi-Stock, iMveliso yoMveliso ukuya kwiiToni
Ifomula yeemolekyuli	I-C72H101N17O26
Ubunzima beMolekyuli	1620.69
Indawo yokunyibilika	202.0~204.0℃
Ukunyibilika	I-Solube kwiMethanol
Uphawu	Ruifu Chemical

Iinkcukacha:

Into	Iinkcukacha
Imbonakalo	Umgubo oMthubi okanye oMthubi
Ukuchongwa kwe-HPLC	Ixesha lokugcinwa kwencopho enkulu yesisombululo sesampulu kufuneka ihambelane naleyo yomgangatho wereferensi.
Ukuchongwa kwe-IR	Uluhlu lwe-IR yomzekelo wovavanyo kufuneka luhambelane nomgangatho wereferensi we-IR.
Imbonakalo yesisombululo	Ukucaca Isisombululo kufuneka sicace okanye singacacisi ngakumbi kunokumiswa kwereferensi II.
Ujikelezo oluKhethekileyo lwe-Optical	+17.0 ° ukuya +25.0 °
pH	4.0 ukuya ku-5.0
Intsalela kwi-Ignition	≤1.0%
I-Anhydro-Daptomycin	≤2.5%
β-Isomere	≤0.50%
Ukungacoceki kweHydrolysis	≤0.50%
Ukungcola 1	≤0.75%
Ukungacoceki 2	≤0.75%
Ukungahlambuluki 3	≤0.75%
Nakuphi na Okunye Ukungcola	≤0.15%
Ukungcola ngokupheleleyo	≤5.0%
Iintsimbi ezinzima	≤30ppm
Amanzi	≤5.0%
Ubunyulu	≥95.0% (Ibalwe kwisiseko esomileyo)
Iintsholongwane ze-Endotoxins	<0.3EU/mg
Izinyibilikisi ezishiyekileyo n-Butanol	≤5000ppm
IiResidualSolvents Isopropanol	≤5000ppm
I-Residual Solvents Ethanol	≤5000ppm
Umlinganiselo weMicrobial TAMC	≤100cfu/g
Umlinganiselo weMicrobial TYMC	≤10cfu/g
E.Coil	Ayifunyanwa
Umgangatho woVavanyo	Umgangatho woShishino
Iimeko zokuGcina	Londoloza kwizikhongozeli eziqinileyo, kwaye ugcine ku -25~-10℃.
Ukusetyenziswa	I-Active Pharmaceutical ingredient (API)

Ukupakishwa kunye noGcino:

Iphakheji: Ibhotile, ingxowa yefoyile yeAluminiyam, igubu lekhadibhodi, 25kg/Igubu, okanye ngokwemfuno yomthengi.

Imeko yoGcino:Gcina kwizikhongozeli ezivaliweyo kwindawo epholileyo neyomileyo;Khusela ekukhanyeni, ukufuma kunye nokuhlaselwa zizinambuzane.

Izinto eziluncedo:

FAQ:

Isicelo:

I-Daptomycin (i-CAS: 103060-53-3) luhlobo lwe-cyclic lipopeptide antibiotics kunye nesakhiwo senoveli.Ikhutshwe kwi-Streptomyces fermentation broth.Ifunyenwe yiNkampani ye-Eli Lilly kwiminyaka yoo-1980, kwaye yaphuhliswa ngempumelelo ngo-1997 yiCubist Pharmaceuticals.Ayineli nje ukuba nolwakhiwo lweekhemikhali ezinoveli kodwa inendlela yokwenza eyahlukileyo kulo naliphi na i-antibiotic eyamkelwe ngaphambili: inqanda iseli ngokuphazamisa ukuthuthwa kwee-amino acids nge-cell membrane, ngaloo ndlela ivalela udonga lweseli ye-peptidoglycan biosynthesis kunye nokutshintsha ubume be-amino acid. inwebu yeseli.Inokutshabalalisa umsebenzi we-membrane yeeseli zebhaktiriya kwiinkalo ezininzi, kwaye ibulale ngokukhawuleza ibhaktheriya yegram-positive.Ukongeza kwindima yokuthatha impembelelo kwiibhaktheriya ezininzi zegram-positive, okona kubaluleke kakhulu, i-Daptomycin inokusebenza okunamandla ekuphatheni iintlobo ezizimeleyo ezibonise iimpawu zokuchasana ne-methicillin, i-vancomycin kunye ne-linezolid.Le propati ibaluleke kakhulu kwikliniki kwizigulana ezinosulelo oluqatha.NgoSeptemba 2003, i-US Food and Drug Administration ivume okokuqala ukuba i-Daptomycin (i-CAS: 103060-53-3) ingasetyenziselwa unyango lwezifo ezinzima zesikhumba.NgoMatshi ka-2006, yamkelwa ukunyanga izifo ezosulelayo.NgoJanuwari 2006, ivunyiwe yiKomishoni yaseYurophu kunyango oluthile olunzima lwesikhumba kunye nosulelo lwezicubu ezithambileyo ezibangelwa yintsholongwane yegram-positive.NgoSeptemba 6, i-2007, i-Cubist Pharmaceuticals ibhengeze ukuba i-European Union ivume ichiza layo lokulwa ne-antibacterial, i-Cubicin yonyango lwe-endocarditis yentliziyo elungileyo ebangelwa yi-Staphylococcus aureus usulelo kunye nezifo ezintsonkothileyo zesikhumba kunye nezicubu ezithambileyo ezinxulumene ne-Staphylococcus aureus.